Simon N. Pimstone - Mar 4, 2022 Form 4/A - Amendment Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Role: Director
Signature: /s/ Cassandra Robinson, Attorney-in-fact
Stock symbol: XENE
Transactions as of: Mar 4, 2022
Transactions value $: -$77,000
Form type: 4/A - Amendment
Date filed: 3/8/2022, 08:41 PM
Date Of Original Report: Mar 8, 2022
Previous filing: Nov 16, 2021
Next filing: Mar 14, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	XENE	Common Shares	Sale	-$77K	-2.5K	-1.28%	$30.80	193K	Mar 8, 2022	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.800 to $30.880, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Content

The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.800 to $30.880, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Remarks:

This amendment corrects the share price that was inaccurately reported on the original Form 4 due to a clerical error.